KRYS insider sale notice: 37,895 shares

KRYS: Form 144 sale notice by Daniel S Janney for $10,113,354.42 proceeds on 02/24/2026.

Accepted by SEC EDGAR 02/24/2026 - 04:39 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

KRYS: Form 144 sale notice by Daniel S Janney for $10,113,354.42 proceeds on 02/24/2026. The filing lists the sale of 37,895 common shares and identifies the issuer contact as Merrill Lynch, 555 California Street, San Francisco. The securities trace to a private placement dated 08/25/2017.

Insights

Securities Compliance Analyst

Form 144 registers an insider resale of restricted/common shares and reports gross proceeds.

The notice shows a reported sale of 37,895 common shares with proceeds of $10,113,354.42 on 02/24/2026. The filing references a 08/25/2017 private placement as the origin of the securities.

This is a routine regulatory disclosure of an intended resale under resale rules; cash‑flow treatment and post‑sale holdings are not stated in the excerpt. Subsequent filings or broker records would confirm settlement details.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the Form 144 for KRYS report?

The Form 144 reports a notice of intent to sell 37,895 common shares with reported proceeds of $10,113,354.42 dated 02/24/2026. It cites a private placement dated 08/25/2017.

Who is the selling party in the KRYS Form 144?

The filing names Daniel S Janney as the selling party and provides an address at 2100 Wharton Street, Suite 701, Pittsburgh, PA. The issuer contact shown is Merrill Lynch in San Francisco.

What class of securities is covered in the KRYS Form 144?

The notice covers common shares issued in a private placement dated 08/25/2017. The excerpt identifies the exchange as Nasdaq but does not provide ticker-specific settlement details.

Does the Form 144 state how the proceeds will be used by the seller?

No. The excerpt reports the sale amount and proceeds of $10,113,354.42 but does not disclose the seller's use of proceeds or post‑sale ownership levels.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001198325
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Krystal Biotech, Inc
SEC File Number	001-38210
Address of Issuer	2100 Wharton Street Suite 701 Pittsburgh PENNSYLVANIA 15203
Phone	4125865830
Name of Person for Whose Account the Securities are To Be Sold	Daniel S Janney
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 555 California Street STE 1800 San Francisco CA 94104	13825	3709850.15	29232189	02/24/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/25/2017	Private Placement	Issuer			13825	08/25/2017	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Daniel S Janney 2100 Wharton Street Suite 701 Pittsburgh PA 15203	Common	02/24/2026	37895	10113354.42

144: Remarks and Signature

Remarks	Shares sold via Alta Bioequities LP
Date of Notice	02/24/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/25/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Daniel S Janney
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)